Industry Wire 274

May 21, 2025 Viktor Zarev 0 min read
  1. UnitedHealth Group under criminal investigation for Medicare fraud.
  2. Time publishes 100 most influential people in health for 2025.
  3. Sutter Heath names Jonathan Ma as CFO.
  4. Texas Children’s and MD Anderson get $150M for cancer center.
  5. Epic hit with lawsuit alleging anticompetitive practices.
  6. Northwell CEO Michael Dowling to step down in October.
  7. 25 hospital transparency fines ranked highest to lowest.
  8. Bon Secours Mercy Health names new CIO.
  9. CommonSpirit cuts operating loss despite payor challenges in Q3.
  10. Hospitals slam Newsom for ‘broken promise’ amid proposed Medi-Cal cuts.
Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Cardiology July 27, 2026

The Career Perceptions of Heart Failure Cardiology July 27, 2026

Picture this – you graduate medical school (not easy), you do a three-year internal medicine residency, then a three-year general cardiology fellowship, and another year of fellowship, but you’re paid less than your peers in other subspecialties – congrats, you’re an advanced heart failure cardiologist (AHFTC).

Cardiology Business July 23, 2026

The Cost of Cardiology is Driven by Insurers July 23, 2026

New price transparency data reveals how wildly insurance payments, reimbursements, and facility fees for cardiology swing across insurers and states, which underscores the complexity of U.S. healthcare costs.

Cardiology Pharmaceuticals July 20, 2026

An Oral PCSK9i and What it Means for Merck July 20, 2026

PCSK9 inhibitors are some of the most effective LDL-lowering drugs out there, but they’ve all required injection, and some even refrigeration. That just changed, however, with the FDA’s approval of Merck's Lipfendra (enlicitide), the first ever oral PCSK9i.